NEKTAR
Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. Nektar has a deep and diverse portfolio of investigational medicines in different stages of clinical development for cancer and auto-immune diseases. We are developing these novel immunotherapies, with the potential of harnessing key steps of the “Cancer Immunity Cycle”, in the fight against cancer. Nektar has the following 5 registrational trials with Bempegaldesleukin (BEMPEG: NKTR-214), an investigational CD122-preferential IL-2–pathway agonist that leverages the clinically validated IL-2 pathway to stimulate an antitumor immune response: 1L unresectable or metastatic melanoma, Adjuvant melanoma, Cisplatin-ineligible 1L locally advanced or metastatic urothelial cancer (mUC), Peri-adjuvant cisplatin-ineligible muscle invasive bladder cancer (MIBC), 1L previously untreated advanced renal cell carcinoma (RCC). For more information please visit http://www.immunivation.com; email: medicalaffairs@nektar.com...
More Info Less Info